Matthew Donley - Sucampo Pharmaceuticals Executive VP of HR
EVP
Matthew Donley is Executive VP of HR of Sucampo Pharmaceuticals
| Age | 47 |
| Phone | 301 961-3400 |
| Web | www.sucampo.com |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals operates under Drug Manufacturers - Other classification in USA and traded on NASDAQ General Markets. It employs 1 people. Sucampo Pharmaceuticals (SCMP) is traded on NASDAQ Exchange in USA and employs 139 people. Management Performance
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Munder, Independent Director | ||
| Peter Pfreundschuh, CFO, Principal Financial Officer | ||
| Matthew Donley, Executive VP of HR | ||
| Max Donley, Executive Vice President of Human Resources | ||
| Peter Kiener, Chief Scientific Officer | ||
| Matthias Alder, Executive Vice President - Business Development & Licensing | ||
| Daniel Getman, Independent Chairman of the Board | ||
| Peter Greenleaf, Chairman and CEO | ||
| Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
| Peter Lichtlen, Chief Medical Officer | ||
| Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
| Andrew Smith, Principal Accounting Officer | ||
| Timothy Walbert, Director | ||
| John Johnson, Director | ||
| Paul Edick, Director | ||
| Alex Driggs, Acting General Counsel, Corporate Secretary | ||
| Karen Smith, Director | ||
| Robert Spiegel, Director | ||
| Maureen OConnell, Independent Director | ||
| Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 14.16 | |||
| Return On Asset | 0.0296 | |||
| Profit Margin | 7.80 % | |||
| Operating Margin | 30.77 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 47.09 M | |||
| Shares Owned By Insiders | 35.13 % | |||
| Shares Owned By Institutions | 82.48 % | |||
| Number Of Shares Shorted | 4.59 M | |||
| Price To Earning | (2.77) X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |